BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Farrell AT, Panepinto J, Desai AA, Kassim AA, Lebensburger J, Walters MC, Bauer DE, Blaylark RM, DiMichele DM, Gladwin MT, Green NS, Hassell K, Kato GJ, Klings ES, Kohn DB, Krishnamurti L, Little J, Makani J, Malik P, McGann PT, Minniti C, Morris CR, Odame I, Oneal PA, Setse R, Sharma P, Shenoy S. End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. Blood Adv 2019;3:4002-20. [PMID: 31809537 DOI: 10.1182/bloodadvances.2019000883] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu JZ, Thein SL. Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches. Blood 2022;139:3030-9. [PMID: 35587865 DOI: 10.1182/blood.2021013873] [Reference Citation Analysis]
2 Abu Al Hamayel N, Waldfogel JM, Hannum SM, Brodsky RA, Bolaños-Meade J, Gamper CJ, Jones RJ, Dy SM. Pain Experiences of Adults With Sickle Cell Disease and Hematopoietic Stem Cell Transplantation: A Qualitative Study. Pain Med 2021;22:1753-9. [PMID: 33674866 DOI: 10.1093/pm/pnaa464] [Reference Citation Analysis]
3 Farrell AT, Panepinto J, Carroll CP, Darbari DS, Desai AA, King AA, Adams RJ, Barber TD, Brandow AM, DeBaun MR, Donahue MJ, Gupta K, Hankins JS, Kameka M, Kirkham FJ, Luksenburg H, Miller S, Oneal PA, Rees DC, Setse R, Sheehan VA, Strouse J, Stucky CL, Werner EM, Wood JC, Zempsky WT. End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain. Blood Adv 2019;3:3982-4001. [PMID: 31809538 DOI: 10.1182/bloodadvances.2019000882] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
4 Inusa BPD, Liguoro I, Tayo B, Booth C, Turner C, Dalton NR. Reliability of different estimated glomerular filtration rate as measures of renal function in children with sickle cell disease. Blood Cells Mol Dis 2021;91:102590. [PMID: 34256313 DOI: 10.1016/j.bcmd.2021.102590] [Reference Citation Analysis]
5 Singh SA, Bakshi N, Mahajan P, Morris CR. What is the future of patient-reported outcomes in sickle-cell disease? Expert Rev Hematol 2020;13:1165-73. [PMID: 33034214 DOI: 10.1080/17474086.2020.1830370] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Pittman DD, Hines PC, Beidler D, Rybin D, Frelinger AL, Michelson AD, Liu K, Gao X, White J, Zaidi AU, Charnigo RJ, Callaghan MU. Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers. Blood 2021;137:2010-20. [PMID: 33067606 DOI: 10.1182/blood.2020006020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 d'Humières T, Savale L, Inamo J, Deux JF, Deswarte S, Lionnet F, Loko G, Chantalat C, Damy T, Guillet H, Pham Hung d'Alexandry d'Orengiani AL, Galactéros F, Audureau E, Maitre B, Humbert M, Derumeaux G, Bartolucci P. Cardiovascular phenotypes predict clinical outcomes in sickle cell disease: An echocardiography-based cluster analysis. Am J Hematol 2021;96:1166-75. [PMID: 34143511 DOI: 10.1002/ajh.26271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Tambor E, Robinson M, Hsu L, Chang HY, Al Naber J; coreSCD Panel. coreSCD: multi-stakeholder consensus on core outcomes for sickle cell disease clinical trials. BMC Med Res Methodol 2021;21:219. [PMID: 34666680 DOI: 10.1186/s12874-021-01413-8] [Reference Citation Analysis]
9 Lehrer-Graiwer J, Yokoshima L, Tong B, Love TW. Accelerated approval of Oxbryta® (voxelotor): A case study on novel endpoint selection in sickle cell disease. Contemp Clin Trials 2020;98:106161. [PMID: 33010428 DOI: 10.1016/j.cct.2020.106161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]